
Ascendis Stock: Neutral On Skytrofa’s Launch; Neutral Rating (NASDAQ:ASND)
Solskin Background Skytrofa (TransCon hGH) was approved in both US and EU in August 2021 for pediatric growth hormone deficiency (GHD) indication based on the positive phase 3 heiGHt trial. The indication described in the […]